David Gwyn, Vice President for Life Sciences, Amplexor
Covid-19 has triggered unprecedented disruption to global life sciences and public health, exposing some gaping holes in drug companies’ product insights and regulatory responsiveness. In this webinar, David Gwyn will explore some of the lessons learnt in 2020 to assess how companies might transform their regulatory operations in 2021, improve their adaptability and become better equipped for continued uncertainty.
He will demonstrate how pharmaceutical companies must get their global operations in order and render their regulatory information more tightly interwoven. Whatever organizations’ immediate agenda, an effective plan for 2021 in relation to RIM transformation must be put in place.